Biopharmaceutical in South Korea: South Korea: Generics and Biosimilars Overview

• Publication date: August 2011

About This Report There is growth potential in the South Korean generic drugs industry, driven by high out-of-pocket costs, an aging population and increasing chronic disease. However, there are also numerous resistors to industry growth, and the domestic trend towards development of incrementally modified drugs offers multinational industry players facing patent expiries lucrative partnering opportunities with global potential....

About This Report

There is growth potential in the South Korean generic drugs industry, driven by high out-of-pocket costs, an aging population and increasing chronic disease. However, there are also numerous resistors to industry growth, and the domestic trend towards development of incrementally modified drugs offers multinational industry players facing patent expiries lucrative partnering opportunities with global potential.

What's Included in This Report?


* Insight into the key drivers and resistors to generic drugs uptake in South Korea.

* Analyses biosimilar opportunities in South Korea and factors which could drive or restrict future uptake.

* Assesses major competitors in the generic drugs and biosimilars industry in South Korea.

Key Market Facts

South Korea’s IP and data exclusivity laws have tightened, inhibiting new product opportunities for generic drugs producers. Combined with an increasingly crowded domestic industry and growing pressures on generic pricing and margins, South Korean industry players are utilizing their expertise in product reformulation to produce super-generics and biosimilars.
There is strong government support, both in terms of financing and policy development, for the domestic biosimilars market, but the registration pathway introduced in 2009 is still gaining experience and the enthusiasm of physicians to prescribe new biosimilar offerings will be key to early success.
Multinational industry players have made numerous deals with South Korean industry players already in late stage clinical trials for multiple biosimilar candidates, including monoclonal antibodies, while the introduction of biobetter guidelines will help ensure South Korea remains at the forefront of the biosimilars market going forward.

Why Should You Buy This Report?


* What are the drivers and resistors to generic uptake in South Korea?

* What deal types are industry players entering into when looking to enter or bolster their position in the South Korean generic drugs and biosimilars industry ?

* Which products are facing patent expiry in South Korea?

Generic Drug Industry in South Korea

Summary
South Korea – Introduction
South Korea – Strategic scoping and focus
South Korea – Main Facts
Generic Drugs industry
Biosimilars industry
Related reports
Upcoming related reports
SOUTH KOREA – GENERICS MARKET OVERVIEW
South Korea – Generic Drugs industry dynamics
Generic Drugs volume uptake is less than one third of the industry in South Korea
Generic Drugs value uptake in South Korea is lower than in other key emerging industry s
South Korean generics drugs industry size is larger than many developed and emerging industry s
South Korea – Generic Drugs drivers and resistors
Generic Drugs pricing is high in South Korea compared to many international industry s
Changing drug pricing policies may put substantial pressure on generics drugs margins
Intellectual property rights in South Korea continue to strengthen and favor innovators…
…however, patent infringement lawsuits have historically sided with domestic generics drugs manufacturers
Multinational pharma are now entering the South Korean generics drugs industry
South Korea – Key generics drugs players
Dong-A Pharmaceuticals is South Korea’s leading domestic pharmaceuticals firm
Hanmi Pharmaceuticals is developing super-generics for the global industry
Daewoong Pharmaceutical is exporting generics drugs to multiple Asian industry s
GlaxoSmithKline Korea will form a new generics drugs hub
Pfizer’s established products division will enter South Korea soon
South Korea – Opportunities for the generics drugs market
Incrementally modified drugs are the next area of focus for domestic producers
SOUTH KOREA – BIOSIMILARS MARKET OVERVIEW
South Korea – Drivers of biosimilar uptake
Biotechnology is a priority market for the South Korean government
Biosimilar guidelines were introduced in South Korea in 2009
South Korean business conglomerates have the extensive resources required to develop biosimilars
Domestic biosimilars developers are attracting foreign partners to enter international industry s
South Korea – Key biosimilar players
Celltrion is leading the biosimilars race in South Korea
Samsung has targeted biosimilars as an entry point to the biopharmaceuticals industry
LG Life Sciences developed first-generation biosimilars industry ed in EUR pe
Hanwha Chemical signed a major, global deal with Merck in 2011
Hanall BioPharma is focusing on the US industry and biobetters
South Korea – Opportunities for the biosimilars market
Biologic patent expiries in South Korea
Biosimilar MAbs are set to dominate the biosimilar industry going forward
Second-generation biosimilars
BIBLIOGRAPHY
Publications and online articles
Datamonitor reports and products
APPENDIX
Exchange rates used in this report

Generic Drug in South Korea

South Korea Generic Drug Sales, Us$bn

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, Us$bn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, Krwbn

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, Krwbn, % Chg Y-o-y

• $ 250
• Industry data
• January 2013

Yearly, From 2004 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea

South Korea Generic Drug Sales, % Of Prescription Sales

• $ 250
• Industry data
• January 2013

Yearly, From 2003 To 2021
By Business Monitor International
Source: Korea Pharmaceutical Manufacturers Association (KPMA), BMI

• Industries : Generic Drug
• Countries : South Korea